ABSTRACT

Background: There are gaps in gastroenterologist team members’ understanding of various topics related to biosimilars. We aimed to examine perspectives, views, and attitudes toward biosimilar and shared decision-making (SDM) among gastroenterology team members in Colorado, USA. The ultimate goal was to increase knowledge and awareness of biosimilars and SDM.

Research design and methods: We developed educational materials focused on biosimilars and SDM and distributed them to each participating gastroenterology office. Subsequently, we conducted a survey of all team members from participating offices.

Results: Responses were obtained from 54 gastroenterology team members. Most respondents identified the correct answer regarding biosimilars, the nocebo effect, and SDM. Almost half (47.2%) of respondents scored their level of awareness regarding biosimilars prior to reading our educational materials as poor, and nearly one quarter (26.4%) indicated so for SDM. Improvement in scores after reading our materials was significant for both biosimilars and SDM (i.e. biosimilar: z = 6.276, p-value <0.001 and SDM z = 6.328, p-value <0.001).

Conclusions: Educational efforts effectively increased the low baseline knowledge and awareness of biosimilars and SDM among gastroenterology team members. More educational projects focused on biosimilars and SDM are needed to reduce the nocebo effect and prevent hampering of the cost-savings of biosimilars.

摘要

背景：胃肠病学家团队成员对与生物仿制药相关的各种主题的理解存在差距。我们旨在研究美国科罗拉多州胃肠病学团队成员对生物仿制药和共享决策 (SDM) 的观点、观点和态度。最终目标是提高生物仿制药和 SDM 的知识和意识。

研究设计和方法：我们开发了专注于生物仿制药和 SDM 的教育材料，并将它们分发给每个参与的胃肠病学办公室。随后，我们对参与办公室的所有团队成员进行了调查。

结果：从 54 名胃肠病学团队成员中获得了答复。大多数受访者确定了有关生物仿制药、反安慰剂效应和 SDM 的正确答案。在阅读我们的教育材料之前，几乎一半 (47.2%) 的受访者将他们对生物仿制药的认知程度评为较差，近四分之一 (26.4%) 的受访者表示对 SDM 如此。阅读我们的材料后，生物仿制药和 SDM 的分数都有显着提高（即生物仿制药：z = 6.276，p 值 <0.001 和 SDM z = 6.328，p 值 <0.001）。

结论：教育工作有效地提高了胃肠病学团队成员对生物仿制药和 SDM 的低基线知识和认识。需要更多关注生物仿制药和 SDM 的教育项目，以减少反安慰剂效应并防止阻碍生物仿制药的成本节约。